Core Viewpoint - Medexus Pharmaceuticals has announced a new senior secured credit agreement totaling US$51.0 million, which includes a US$21.0 million term loan and a US$5.0 million revolving loan facility, alongside plans to initiate a normal course issuer bid (NCIB) for its common shares [1][2][3]. Group 1: Credit Facilities - The new credit agreement includes a US$21.0 million term loan facility and a US$5.0 million revolving loan facility, with an additional US$10.0 million delayed draw feature for future licensing and acquisition transactions [1]. - The term loan facility has a maturity date of November 17, 2029, and the weighted average interest rate will initially be 6.74%, which is lower than the previous rate of 6.95% [2]. Group 2: Normal Course Issuer Bid (NCIB) - Medexus intends to commence an NCIB for its common shares, subject to approval from the Toronto Stock Exchange (TSX), allowing the company to purchase up to 10% of its public float over the next 12 months [3]. - The actual number of shares purchased under the NCIB will depend on market conditions and the company's discretion, with the aim of stabilizing the market for its common shares [4]. Group 3: Financial and Operational Outlook - The CFO of Medexus highlighted the significance of the new financing as a non-dilutive option that reflects the company's improving financial and operational profile since the launch of GRAFAPEX™ in February 2025 [2]. - The company is focused on capital allocation strategies that may include share repurchases if the market price is deemed undervalued, which could benefit both the company and its investors [4]. Group 4: Company Overview - Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform, focusing on innovative treatments in hematology, hematology-oncology, rheumatology, and allergy [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple malfunctions, injuries, and deaths related to these defects but failed to take adequate remedial actions [3]. - The complaint states that Baxter's public statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses in Baxter International, Inc. stock during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Insights - Aeries Technology has been recognized for the second consecutive year in Everest Group's PEAK Matrix® Assessment 2025 for its Global Capability Center (GCC) Setup Capabilities, highlighting its strength in supporting mid-market and private equity-backed enterprises [1][2] Group 1: Recognition and Assessment - The PEAK Matrix® is an annual assessment that benchmarks service providers based on vision, capability, and market success, with Aeries being recognized as a Major Contender for its ability to help enterprises establish and optimize GCCs [2] - Aeries Technology's recognition reinforces its position as a trusted transformation partner, focusing on creating GCCs that deliver measurable value through advanced technologies [4] Group 2: GCC Expertise and Delivery Model - Aeries' GCC delivery model combines advisory insight with AI-enabled transformation and digital execution, aiding clients in building scalable global operations [3] - The company provides end-to-end GCC lifecycle support, ensuring faster time-to-value and predictable execution through data-driven program management [5] Group 3: Technology and Compliance - Aeries embeds automation, analytics, and process intelligence in its operating models to enhance integration speed, KPI visibility, and decision accuracy for portfolio-level value creation [5] - The company ensures secure and compliant execution at scale, adhering to global compliance and cybersecurity standards while enabling continuous optimization [5]

Core Perspective - ADIA Nutrition Inc. is updating its SIC code to better reflect its focus on biological products, moving from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) [1][3] Company Operations - The company specializes in regenerative medicine, particularly in the manufacturing and distribution of proprietary biologics [1][7] - ADIA operates through its lab division, Adia Labs LLC, which sells FDA-registered products like AdiaVita and AdiaLink [6][7] - The company is expanding its network of Adia Med clinics that provide specialized regenerative treatments, including stem cell therapy and advanced biologics [6][7] Financial Performance - ADIA reported over 200% revenue growth in Q3 2025, indicating strong business momentum [3] - Revenue streams include service fees, product sales, equity stakes, and insurance billing for healthcare treatments [8] Strategic Partnerships - The company is open to strategic partnerships with clinic owners and healthcare practitioners to expand access to its regenerative therapies [4][8] - ADIA invests in aligned businesses, such as Cement Factory LLC, to enhance its health and wellness focus [8]

Core Insights - Telescope Innovations has been selected by the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) to provide its Self-Driving Lab (SDL) platform for a new R&D facility in Seoul, marking a significant step in Korea's biopharma sector [3][5] - The SDL technology utilizes robotics, inline analytics, and AI to optimize experiments, potentially reducing drug development timelines significantly [4][5] - This initiative is part of KPBMA's broader mission to support R&D and innovation in the pharmaceutical industry, with the SDL serving as a training hub for researchers [7][8] Company Overview - Telescope Innovations is recognized as a leading developer of Self-Driving Lab systems, focusing on scalable manufacturing processes and tools for the pharmaceutical and chemical industries [11] - The company aims to enhance experimental throughput, efficiency, and data quality through its advanced technologies [11] Industry Impact - The deployment of SDLs is expected to accelerate the transition towards automated and digital R&D in Korea, with implications for various sectors including pharmaceuticals, agriculture, and energy [5][9] - The partnership with KPBMA positions Telescope at the forefront of the growing market for lab automation and digital transformation in Asia [8][9]

Core Points - CAT Strategic Metals Corporation is conducting a Rights Offering, allowing shareholders to subscribe for additional units at a set price [1][2] - Each unit consists of one common share and one purchase warrant, with specific pricing and terms outlined [2][3] - The offering includes provisions for oversubscription, allowing shareholders to acquire more units if the offering is not fully subscribed [3] Rights Offering Details - Shareholders will receive one transferable right for each common share held, with a subscription price of $0.0075 per unit [2] - Each whole warrant allows the purchase of an additional common share at $0.05 for a period of 60 months post-offering [2] - Rights expire at 4:00 p.m. Pacific Time on November 21, 2025, and trading will cease at 12:00 p.m. Eastern Time on the same day [8] Company Overview - CAT Strategic Metals focuses on acquiring and advancing mineral properties, particularly in lithium, copper, gold, silver, and tellurium [7] - The company controls several projects, including the Gold Jackpot property in Nevada and the South Preston Uranium Project in Saskatchewan [7] - CAT's shares are traded on the Canadian Securities Exchange under the symbol "CAT" and on the Frankfurt Stock Exchange as "8CHA" [7]

Core Viewpoint - Thunder Gold Corp. is set to host an investor update on November 25, 2025, focusing on its Phase 3 drill program and the advancement of the Tower Mountain Gold Project as a significant opportunity in the gold sector heading into 2026 [1][2]. Company Overview - Thunder Gold Corp. is advancing the Tower Mountain Project located in Thunder Bay, Ontario, which is characterized as an emerging gold system with the potential for a long-life, open-pit operation [4]. - The Tower Mountain Gold Property spans 2,500 hectares and is strategically located near the Trans-Canada highway, approximately 40 km from Thunder Bay [3]. Exploration Strategy - The company is implementing a low-cost exploration strategy aimed at defining a large-tonnage, low-grade gold system [2]. - Historical drilling has revealed anomalous gold extending over 500 meters along an 1,800-meter strike length and to depths exceeding 500 meters from the surface, indicating significant exploration potential [3]. Development Goals - Thunder Gold is progressing towards its first NI 43-101 Mineral Resource Estimate, with the goal of establishing a lower-capex, near-surface gold resource that supports a viable development pathway [5]. - The company aims to provide third-party validation of the asset's scale and longevity, enhancing its competitive positioning among peers [5]. Competitive Advantages - The Tower Mountain Project benefits from industry-leading drilling costs, existing infrastructure, and access to a skilled local workforce, making it a unique opportunity for cost-effective growth [6]. - The vision of the company is to unlock a discovery that could transform the Canadian gold project landscape, delivering long-term value for shareholders [6].

Core Viewpoint - PesoRama Inc. is expanding its presence in Mexico with the opening of three new stores, enhancing accessibility for consumers and reinforcing its growth strategy [1][5]. Group 1: Store Openings - Store 29 is located in Roma Norte, covering 6,340 square feet, and is set to open on November 21, 2025, benefiting from high pedestrian traffic due to its proximity to the Durango Metrobús station [2]. - Store 30 will be the first in downtown Mexico City, approximately 1 km from Zócalo, with a size of 6,620 square feet, scheduled to open on December 13, 2025 [3]. - Store 31 will be PesoRama's first location in Puebla, situated in a shopping mall, covering 4,585 square feet, and is planned to open on December 21, 2025 [4]. Group 2: Company Strategy and Vision - The openings of these stores are part of PesoRama's strategy to increase accessibility for Mexican consumers and to establish a robust presence in high-density traffic areas [5]. - The company aims to reach every Mexican home through its expansion efforts, indicating a commitment to growth and market penetration [4][5]. - PesoRama operates under the JOi Dollar Plus brand, focusing on value retailing with a consistent merchandise offering across various categories [8].

Core Points - The announcement by Prime Minister Carney regarding the Northwest Critical Conservation Corridor and the Yukon-B.C. Grid Connect aims to accelerate the development of this significant infrastructure project [1][2] - The Yukon-B.C. Grid Connect is expected to enhance energy security, facilitate clean power transmission, and support critical minerals development in the Yukon, particularly benefiting the Casino Project [3][4] Company Overview - Western Copper and Gold Corporation is advancing the Casino Project, recognized as Canada's premier copper-gold mine and one of the most economically viable greenfield mining projects globally [5] - The company is committed to collaborating with First Nations and local communities, employing responsible mining technologies and practices [6] Economic Impact - The Yukon-B.C. Grid Connect could generate up to C$7.6 billion annually in clean economic growth, create over 36,000 long-term jobs, and enable the addition of up to 2,000 MW of new renewable energy [4] - The Casino Project is identified as a potential anchor tenant that could provide stable baseload demand, enhancing the economic viability of the transmission line [4][5]

New Glasgow, Nova Scotia--(Newsfile Corp. - November 17, 2025) - Crombie Real Estate Investment Trust (TSX: CRR.UN) ("Crombie") today announced a distribution of $0.07500 per Unit for the period from November 1, 2025, to and including November 30, 2025. The distribution will be payable on December 15, 2025, to Unitholders of record as at November 30, 2025.About Crombie REITCrombie invests in real estate with a vision of enriching communities together by building spaces and value today that leave a positive ...